Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The person must be female
- The person must have a confirmed diagnosis of abnormal breast tissue growth (breast heteroplasia)
- The person must be 18 years of age or older
- The person must have a medical recommendation for chemotherapy given before surgery (neoadjuvant chemotherapy)
- The person must be willing to attend regular cancer follow-up appointments as part of standard care
- People with newly diagnosed cancer that has spread to other parts of the body (de novo metastatic disease) who are receiving chemotherapy as their primary treatment and are suitable for a biopsy of the original tumour may also be considered
- The person must be willing to take part in the study and must sign and date a consent form agreeing to participate
Who may not be able to join:
- People who have already received chemotherapy treatment in the past
- People who do not have a confirmed laboratory-based diagnosis (from cell or tissue testing) of breast cancer
- People who have been diagnosed with other solid tumours in addition to the breast condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +390382592272
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Establishment of Patient-Derived Organoids of Breast Cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.